There are no upcoming events at this time.

April 18, 2024 at 10:00 AM ET

March 18, 2024, 3:00 PM PST

June 2, 2022

April 2 - 4, 2022

September 29, 2021

View our presentation here

September 13-15, 2021

Tenax Therapeutics will present a company overview and hold virtual investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021.

Webcast link to the presentation can be found here and will be available for up to 90 days after the conference.

August 16, 2021

The webinar will feature a presentation by Key Opinion Leader (KOL) Daniel Burkhoff, M.D., Ph.D. (Cardiovascular Research Foundation) who will discuss the current treatment landscape and unmet medical need in treating patients with pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) and how Levosimendan could become an important new treatment option for this patient population. Dr. Burkhoff will be available to answer questions following the formal presentations.

Tenax's Chief Medical Officer, cardiologist Stuart Rich, M.D., will then discuss the clinical development plan for their novel therapy Levosimendan, a first-in-class K-ATP activator/ calcium sensitizer, as the first treatment for PH-HFpEF (WHO Group 2 Pulmonary Hypertension).

A live Q&A session will follow the formal presentations.

Watch the replay: https://media.rampard.com/20210816/

January 21, 2021

In addition, the conference call can be accessed by dialing (877) 405-1242 from the U.S. and (201) 389-0852 internationally, followed by the conference ID: 13715313.

An archived webinar recording of the event will be available on the website for approximately 30 days.

December 23, 2020

November 18, 2020